Division of Pediatric Endocrinology and Diabetology, Center of Child and Adolescent Medicine, Justus Liebig University, Giessen, Germany.
Steroids. 2012 Nov;77(13):1391-7. doi: 10.1016/j.steroids.2012.08.001. Epub 2012 Aug 23.
The 'backdoor' pathway provides an efficient route from 17α-hydroxyprogesterone (17-OHP) to dihydrotestosterone (DHT) in patients with 21-hydroxylase deficiency (21-OHD). 17-OHP is a good substrate for 5α-reductase leading to 17α-hydroxyallopregnanolone, which is an excellent substrate for the 17,20-lyase activity of CYP17A1. 5α-Reductase and CYP17A1 are therefore two crucial enzymes in the backdoor route. The 17,20-lyase activity of CYP17A1 additionally promotes the conversion of 17-OHP and 17α-hydroxypregnenolone to androgens in the classical Δ(4) and Δ(5) pathways. Thus, we hypothesised that the activities of 5α-reductase and 17,20-lyase should determine the flux through the androgen synthesis pathways in patients with 21-OHD.
We compared retrospectively urinary steroid hormone profiles determined by gas chromatography-mass spectrometry of 142 untreated 21-OHD patients (age range: 1 day to 25.4 years; 51 males) with 138 control subjects.
The relative activities of the backdoor pathway and 5α-reductase correlated significantly (p<0.0001). Neonates with 21-OHD demonstrated a moderate activity of the 5α-reductase leading to moderate 17α-hydroxyallopregnanolone generation in the backdoor pathway. Due to substantial 17,20-lyase activity, 17α-hydroxyallopregnanolone is converted rapidly to androsterone. During infancy, the activity of 5α-reductase is very high leading to a high activity of the backdoor pathway until the generation of 17α-hydroxyallopregnanolone. Only a moderate androsterone production is the result of low 17,20-lyase activity. Children show a low 5α-reductase and a high 17,20-lyase activity leading to a low androsterone generation via the backdoor pathway.
The 5α-reductase is the gatekeeper of the backdoor pathway, whereas the 17,20-lyase activity of CYP17A1 is the regulator of the flux through the androgen pathways.
21-羟化酶缺乏症(21-OHD)患者体内的 17α-羟孕酮(17-OHP)可通过“旁路”途径高效转化为二氢睾酮(DHT)。17-OHP 是 5α-还原酶的良好底物,生成 17α-羟基雄烯二酮,后者是 CYP17A1 的 17,20-裂解酶活性的极佳底物。因此,5α-还原酶和 CYP17A1 是旁路途径中的两个关键酶。CYP17A1 的 17,20-裂解酶活性还可促进 17-OHP 和 17α-羟孕烯醇酮向经典的 Δ(4)和 Δ(5)途径转化为雄激素。因此,我们假设 5α-还原酶和 17,20-裂解酶的活性应决定 21-OHD 患者的雄激素合成途径中的通量。
我们通过气相色谱-质谱联用技术对 142 例未经治疗的 21-OHD 患者(年龄范围:1 天至 25.4 岁;男性 51 例)和 138 例对照者的尿甾体激素谱进行了回顾性比较。
旁路途径和 5α-还原酶的相对活性显著相关(p<0.0001)。21-OHD 新生儿具有中等强度的 5α-还原酶活性,导致旁路途径中生成中等强度的 17α-羟基雄烯二酮。由于 17,20-裂解酶活性较大,17α-羟基雄烯二酮迅速转化为雄酮。在婴儿期,5α-还原酶活性非常高,导致旁路途径的活性很高,直到生成 17α-羟基雄烯二酮。由于 17,20-裂解酶活性较低,仅产生中等强度的雄酮。儿童的 5α-还原酶活性较低,17,20-裂解酶活性较高,导致通过旁路途径生成的雄激素生成量较低。
5α-还原酶是旁路途径的“守门员”,而 CYP17A1 的 17,20-裂解酶活性是雄激素途径通量的调节因子。